Detalhe da pesquisa
1.
Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis.
Biol Blood Marrow Transplant
; 25(11): 2267-2273, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31288096
2.
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.
Biol Blood Marrow Transplant
; 22(3): 432-40, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26493563
3.
Financial burden in recipients of allogeneic hematopoietic cell transplantation.
Biol Blood Marrow Transplant
; 20(9): 1375-81, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24867778
4.
Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
Biol Blood Marrow Transplant
; 19(8): 1167-74, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23664940
5.
Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis.
Blood Cancer J
; 10(3): 36, 2020 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32157091
6.
Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis.
Bone Marrow Transplant
; 54(2): 204-211, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29795431
7.
Myeloid neoplasm with eosinophilia associated with isolated extramedullary FIP1L1/PDGFRA rearrangement.
Cancer Genet
; 220: 13-18, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29310833
8.
Impact of race and ethnicity on outcomes and health care utilization after allogeneic hematopoietic cell transplantation.
Leuk Lymphoma
; 56(4): 987-92, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25012944
9.
Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase.
Leuk Res
; 36(9): 1147-51, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22578777
10.
Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies.
Leuk Lymphoma
; 56(1): 226-9, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24707940
11.
Ruxolitinib in clinical practice for therapy of myelofibrosis: single USA center experience following Food and Drug Administration approval.
Leuk Lymphoma
; 55(1): 195-7, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23647081